{"id":52696,"date":"2023-01-09T16:02:05","date_gmt":"2023-01-09T15:02:05","guid":{"rendered":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/"},"modified":"2023-01-09T16:02:05","modified_gmt":"2023-01-09T15:02:05","slug":"dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international","status":"publish","type":"post","link":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/","title":{"rendered":"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International"},"content":{"rendered":"
\n

NEW YORK–(BUSINESS WIRE)–DLA Piper advised Arlington Capital Partners and Everest Clinical Research (Everest), a leading full-service contract research organization (CRO) with expertise in biostatistics and statistical programming, in its acquisition of Brightech International (Brightech), a leading CRO that specializes in complex, value-add biostatistics, programming and clinical data management services.\n<\/p>\n

<\/a><\/p>\n

\nThe acquisition of Brightech will help Everest expand its capabilities and global footprint, deepen its R&D resources, and accelerate its growth. Brightech will continue to be led by its existing management team.\n<\/p>\n

\n\u201cThe acquisition of Brightech will provide Everest with the opportunity to expand its world class capabilities and its geographic reach,\u201d said Jeffrey Houle, co-chair of DLA Piper\u2019s Aerospace, Defense and Government Services Transactional Practice, who led the deal team. \u201cIt was a pleasure working with Arlington Capital Partners and Everest to combine these two highly respected teams at the forefront of innovation in the industry.\u201d\n<\/p>\n

\nAlong with Houle (Washington, DC), the DLA Piper team that advised Arlington Capital Partners and Everest included partners Julia Kovacs, Richard Newcomb, and Jennifer Kashatus (Washington, DC), Thomas Pilkerton III and Jordan Bailowitz (Baltimore), Christopher Mikson, MD (Philadelphia), Sarah Tauman (San Francisco), Nate McKitterick (Palo Alto), Russel Drew and Kevin Fritz (Toronto), Qiang Li (Shanghai), J Carolyn Bigg and Johnny Choi (Hong Kong) and Amanda Ge (Beijing); and associates Josh Feldman (Baltimore), Xu Zhou (Shanghai) and Venus Cheung (Hong Kong).\n<\/p>\n

\nWith more than 1,000 corporate lawyers globally, DLA Piper helps clients execute complex transactions seamlessly while supporting clients across all stages of development. The firm has been rated number one in global M&A volume for 12 consecutive years, according to Mergermarket<\/i>.\n<\/p>\n

\nWith more than 125 US lawyers who provide strategic counsel to private equity funds and their industry-leading portfolio companies, DLA Piper\u2019s Private Equity practice has the capacity, experience and relationships to help drive value across the investment life cycle by delivering responsive, efficient and integrated solutions around the world.\n<\/p>\n

\nAbout Everest Clinical Research Corporation<\/b>\n<\/p>\n

\nEverest is a full-service contract research organization (\u201cCRO\u201d) providing a broad range of expertise-based clinical research services to worldwide pharmaceutical, biotechnology, and medical device industries. Everest serves some of the best-known companies and works with many of the most advanced drugs, biologics, and medical devices in development today. Founded in 2004, Everest has a strong foundation as a statistical and data management center of excellence. Building on this foundation, Everest has successfully developed and established itself as a full-service CRO. Operating primarily in North America, with offices in Toronto, Ontario, Canada, New Jersey, USA, Shanghai, China, and Taipei, Taiwan, Everest is known in the industry for its high-quality deliverables, superior customer service, and flexibility in meeting clients\u2019 needs.\n<\/p>\n

\nAbout Arlington Capital Partners<\/b>\n<\/p>\n

\nArlington Capital Partners is a Washington, DC-based private equity firm that has managed approximately US$7 billion in capital commitments. Arlington is focused on middle market investment opportunities in growth industries including healthcare, government services and technology, aerospace & defense, and business services and software. The firm\u2019s professionals and network have a unique combination of operating and private equity experience that enable Arlington to be a value-added investor. Arlington invests in companies in partnership with high quality management teams that are motivated to establish and\/or advance their Company\u2019s position as leading competitors in their field.\n<\/p>\n

\nAbout DLA Piper<\/b>\n<\/p>\n

\nDLA Piper is a global law firm with lawyers located in more than 40 countries throughout the Americas, Europe, the Middle East, Africa and Asia Pacific, positioning us to help clients with their legal needs around the world. In certain jurisdictions, this information may be considered attorney advertising. dlapiper.com<\/a>\n<\/p>\n

Contacts<\/b> <\/p>\n

\nGeneva Youel, Media Relations, DLA Piper, +1 213 330 7779\n<\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK–(BUSINESS WIRE)–DLA Piper advised Arlington Capital Partners and Everest Clinical Research (Everest), a leading full-service contract research organization (CRO) with expertise in biostatistics and statistical programming, in its acquisition of Brightech International (Brightech), a leading CRO that specializes in complex, value-add biostatistics, programming and clinical data management services. The acquisition of Brightech will help … [Read more…]<\/a><\/span><\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[13],"tags":[],"class_list":{"0":"entry","1":"post","2":"publish","3":"author-business","4":"post-52696","6":"format-standard","7":"category-industry"},"yoast_head":"\nDLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International - Pharma Trend<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International - Pharma Trend\" \/>\n<meta property=\"og:description\" content=\"NEW YORK–(BUSINESS WIRE)–DLA Piper advised Arlington Capital Partners and Everest Clinical Research (Everest), a leading full-service contract research organization (CRO) with expertise in biostatistics and statistical programming, in its acquisition of Brightech International (Brightech), a leading CRO that specializes in complex, value-add biostatistics, programming and clinical data management services. The acquisition of Brightech will help ... [Read more...]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/\" \/>\n<meta property=\"og:site_name\" content=\"Pharma Trend\" \/>\n<meta property=\"article:published_time\" content=\"2023-01-09T15:02:05+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/mms.businesswire.com\/media\/20230109005132\/en\/1679584\/21\/DLA_Piper_Logo.jpg\" \/>\n<meta name=\"author\" content=\"Business Wire\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Business Wire\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/\"},\"author\":{\"name\":\"Business Wire\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\"},\"headline\":\"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International\",\"datePublished\":\"2023-01-09T15:02:05+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/\"},\"wordCount\":619,\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005132\\\/en\\\/1679584\\\/21\\\/DLA_Piper_Logo.jpg\",\"articleSection\":[\"Industry\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/\",\"name\":\"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International - Pharma Trend\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005132\\\/en\\\/1679584\\\/21\\\/DLA_Piper_Logo.jpg\",\"datePublished\":\"2023-01-09T15:02:05+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/#primaryimage\",\"url\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005132\\\/en\\\/1679584\\\/21\\\/DLA_Piper_Logo.jpg\",\"contentUrl\":\"https:\\\/\\\/mms.businesswire.com\\\/media\\\/20230109005132\\\/en\\\/1679584\\\/21\\\/DLA_Piper_Logo.jpg\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"name\":\"Pharma Trend\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#organization\",\"name\":\"Pharma Trend\",\"url\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"\",\"contentUrl\":\"\",\"caption\":\"Pharma Trend\"},\"image\":{\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/pharma-trend.com\\\/en\\\/#\\\/schema\\\/person\\\/02d41342c7a74fa7f0032bb35ef0bb24\",\"name\":\"Business Wire\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International - Pharma Trend","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/","og_locale":"en_US","og_type":"article","og_title":"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International - Pharma Trend","og_description":"NEW YORK–(BUSINESS WIRE)–DLA Piper advised Arlington Capital Partners and Everest Clinical Research (Everest), a leading full-service contract research organization (CRO) with expertise in biostatistics and statistical programming, in its acquisition of Brightech International (Brightech), a leading CRO that specializes in complex, value-add biostatistics, programming and clinical data management services. The acquisition of Brightech will help ... [Read more...]","og_url":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/","og_site_name":"Pharma Trend","article_published_time":"2023-01-09T15:02:05+00:00","og_image":[{"url":"https:\/\/mms.businesswire.com\/media\/20230109005132\/en\/1679584\/21\/DLA_Piper_Logo.jpg","type":"","width":"","height":""}],"author":"Business Wire","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Business Wire","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/#article","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/"},"author":{"name":"Business Wire","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24"},"headline":"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International","datePublished":"2023-01-09T15:02:05+00:00","mainEntityOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/"},"wordCount":619,"publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005132\/en\/1679584\/21\/DLA_Piper_Logo.jpg","articleSection":["Industry"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/","url":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/","name":"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International - Pharma Trend","isPartOf":{"@id":"https:\/\/pharma-trend.com\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/#primaryimage"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/#primaryimage"},"thumbnailUrl":"https:\/\/mms.businesswire.com\/media\/20230109005132\/en\/1679584\/21\/DLA_Piper_Logo.jpg","datePublished":"2023-01-09T15:02:05+00:00","breadcrumb":{"@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/#primaryimage","url":"https:\/\/mms.businesswire.com\/media\/20230109005132\/en\/1679584\/21\/DLA_Piper_Logo.jpg","contentUrl":"https:\/\/mms.businesswire.com\/media\/20230109005132\/en\/1679584\/21\/DLA_Piper_Logo.jpg"},{"@type":"BreadcrumbList","@id":"https:\/\/pharma-trend.com\/en\/dla-piper-advises-arlington-capital-partners-and-everest-clinical-research-in-its-acquisition-of-brightech-international\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/pharma-trend.com\/en\/"},{"@type":"ListItem","position":2,"name":"DLA Piper Advises Arlington Capital Partners and Everest Clinical Research in Its Acquisition of Brightech International"}]},{"@type":"WebSite","@id":"https:\/\/pharma-trend.com\/en\/#website","url":"https:\/\/pharma-trend.com\/en\/","name":"Pharma Trend","description":"","publisher":{"@id":"https:\/\/pharma-trend.com\/en\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/pharma-trend.com\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/pharma-trend.com\/en\/#organization","name":"Pharma Trend","url":"https:\/\/pharma-trend.com\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/","url":"","contentUrl":"","caption":"Pharma Trend"},"image":{"@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/pharma-trend.com\/en\/#\/schema\/person\/02d41342c7a74fa7f0032bb35ef0bb24","name":"Business Wire"}]}},"_links":{"self":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52696","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/comments?post=52696"}],"version-history":[{"count":0,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/posts\/52696\/revisions"}],"wp:attachment":[{"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/media?parent=52696"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/categories?post=52696"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharma-trend.com\/en\/wp-json\/wp\/v2\/tags?post=52696"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}